Mun

When Volume Matters, Immunoassay Systems Deliver

Although new and innovative technology has enabled more and more laboratory testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests a...

Immunoassay Systems - Your Laboratory Workhorse

Although new and innovative technology has enabled more and more laboratory testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests a...

Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

MILWAUKEE, July 11, 2007 /PRNewswire/ -- A new study suggestsstrong variation in the occurrence of anaphylaxis between thenorthern and southern U.S. Anaphylaxis is a severe allergicreaction that can be fatal without treatment with epinephrine. Thestriking north-south differences in EpiPen prescribing, a marker ofanaphylaxis risk, currently are without explanation. Theinvestigators hypoth...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

PHILADELPHIA, July 3, 2007-- One of the fundamental traits of atumor – how it avoids the immune system – might becomeits greatest vulnerability, according to researchers from theUniversity of Southern California. Their findings,demonstrated in human breast and colorectal cancers, indicate thata technique for determining a tumor’s “immunesignature,” could be...

First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy

ROANOKE, Va.--(BUSINESS WIRE)--Jun 20, 2007 - Researchers from LunaInnovations Incorporated (NASDAQ: LUNA) and Virginia CommonwealthUniversity (VCU) are the first to show that carbon nanospheres,sometimes referred to as "buckyballs," are able to block allergicresponse in human cell culture experiments and mice. These findingsare described in a paper entitled "Fullerene Nanomaterials Inhibit...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

HIGH WYCOMBE, UK 18th June 2007-Previously undisclosedpre-clinical data showing how a new flu vaccine has the potentialto protect against all strains of influenza, including pandemic andannual, was presented today by PepTcell, at the 2007 Options forthe Control of Influenza VI (Options) Conference, in Toronto,Canada. The pre-cli...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

Data Presented at Leading Influenza Conference HIGH WYCOMBE, England, June 18, 2007 /PRNewswire/ -- Previouslyundisclosed pre-clinical data showing how a new flu vaccine has thepotential to protect against all strains of influenza, includingpandemic and annual, was presented today by PepTcell, at the 2007Options for the Control of Influenza VI (Options) Conference, inToronto, Canada....

July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Results from thesuccessful clinical trial of Oscient Pharmaceuticals' (Nasdaq:OSCI) FACTIVE(R) (gemifloxacin mesylate) tablets for the five-daytreatment of community-acquired pneumonia of mild to moderateseverity (CAP) have been published in the July issue of thepeer-reviewed Journal of Antimicrobial Chemotherapy, currentlyavailable in advance...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - GeronCorporation (Nasdaq:GERN) today announced the presentation ofresearch studies indicating that GRNOPC1, the company's humanembryonic stem cell (hESC)-based therapeutic for the treatment ofspinal cord injury, evades a direct attack by the human immunesystem. Presented by Geron scientist Ross Okamura at the Federation ofClinical Immun...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

- Results Presented at the 12th Congress of European HematologyAssociation (EHA) - VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that data presented at the 12th Congressof EHA in Vienna, Austria, showed positive responses in patie...

Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, made a posterpresentation at the 2007 Annual Meeting of the Federation ofClinical Immunology Societies (FOCIS) in San Diego June 7-11 at theSheraton San Diego Hotel & Marina. The poster, entitled"Identifying New Immuno...

Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency

THE WOODLANDS, Texas, June 08, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today announced the publication ofnew findings from a joint research project with scientists at FoxChase Cancer Center in Philadelphia, PA. Together with David L.Wiest, Ph.D., Lexicon researchers have discovered a novel andsurprising role for ribosomal protein L22 (Rpl22) in thedevelopment of T lym...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that initial results from a Phase I studywith the Company's humanized anti-MUC1 monoclonal antibody (hPAM4),labeled with...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 InhibitorReveal Further Evidence of Safety, Tolerability, and BiologicalActivity CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced updated interimresults from a Phase I clinical trial of the companies' heat shockpr...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...

Encouraging Clinical Activity of GSK's Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer

GSK Announces Launch of Largest Ever Phase III Clinical Trial inLung Cancer Treatment PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline today announced final results of a Phase IIproof-of-concept clinical trial of its investigational MAGE-A3Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3positive patients with stage IB or II Non-Small Cell Lung Cancer(NSCLC)...

Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gavea presentation titled "RAS peptide vaccination in resectedpancreatic cancer patients - persistence of anti tumour responseand long term survival" at ASCO's (American Society of ClinicalOncology) annual cancer meeting. A follow-up study of 23 resected pancreatic cancer...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., June 04, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announcedfollow-up data from a Phase 2 clinical trial of GVAX immunotherapyfor pancreatic cancer which was conducted by the Johns HopkinsSidney Kimmel Cancer Center. The trial enrolled 60 patients withoperable pancreatic cancer who received GVAX after surgicalresection of their tumor and adjuvant...

Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases

- Initial Phase II Study Results Presented at Society of NuclearMedicine Annual Meeting - WASHINGTON, June 04, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that its anti-carcinoembryonic antigen(CEA) antibody, labetuzumab, labeled with the radioisotope,i...

CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted toinform you about the upcoming scientific presentations of its novelimmunotherapeutic CYT003-QbG10 to treat allergic diseases.Recently, positive clinical results for CYT003-QbG10 were obtainedand will be presented in different sessions at the XXVI Congress ofthe European Academy of Allergology and Clinical Immunology(EAACI), takin...

CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine companyfocused on the development and commercialization ofmultifunctional, tumor-targeted therapies today presented a posterabstract at the 43rd American Society of Clinical Oncology (ASCO)Annual meeting. The poster, entitled "Preliminary Results of aPhase 1 Clinical Trial of CYT-6901," announced the preliminary dataof a National Ca...

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinicaldata on IPI-504 in a Phase I trial in patients withgastrointestinal stromal tumors (GIST) and other soft tissuesarcomas (STS), will be presented at the 2007 Annual Meeting of theAmerican Society of Clini...

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...

Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data

CHAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- With enormousinvestments and the success of a pharmaceutical product at play,pharmaceutical firms need to develop effective strategies forcommunicating clinical trial results early. Companies that mastertheir communication planning and execution will gain a significantadvantage in the marketplace. According to research and consulting...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc.(Nasdaq: IMGN), a biopharmaceutical company that develops targetedanticancer therapeutics using its Tumor-Activated Prodrug (TAP)technology, today announced that clinical findings for threedifferent TAP compounds for the treatment of solid tumors are to bereported at the 43rd American Society of Clinical Oncology (ASCO)Annual...

MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations

Data Include Results from Phase 1 Studies with Monoclonal AntibodyTargeting Interleukin-9 (IL-9); Preclinical Data Provide FurtherRationale for IL-9 Inhibition in Developing Potential AsthmaTherapies GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the presentation of datahighlighting recent progress within the company's inflammatorydisease pipelin...

CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals

VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 increased the immune responseagainst H5 avian influenza antigen in combination with MAS-1, awater-in-oil adjuvant delivery system. These findings werepresented on May 23, 2007 by Dr. Daniel Zimmerman, Senior VicePresident of Research, Cellular Immunology at CEL-SCI at theAmerican Society of Mic...

VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals'novel pandemic influenza vaccine candidates triggered protectiveimmune responses in pre-clinical challenge studies, according todata presented for the first time today at the Third InternationalConference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic consensus DNA vaccines toprotect against a leth...

Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohn's Disease

WASHINGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM), anindividualized oral immune regulation preparation, may be aneffective treatment for moderate-to-severe Crohn's disease. Interimdata from two ongoing double-blind, placebo controlled Phase IIstudies suggest that this investigational approach induced goodclinical remissions and improved patients' quality of life comparedto placebo. Me...

InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting

Reports 'Picomolar' Potency and Slow Dissociation from HCVProtease WASHINGTON, May 21, 2007 /PRNewswire-FirstCall via COMTEX NewsNetwork/ -- InterMune, Inc. (Nasdaq: ITMN) today presented newpreclinical data on the company's Hepatitis C virus (HCV) NS3/4Aprotease inhibitor, ITMN-191, during a scientific session of theDigestive Disease Week (DDW) meeting being held May 19-24 inW...

Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

VIENNA, Austria, May 18, 2007 – Intercell AG (VSE,“ICLL”) has been informed by its strategic partnerMerck & Co., Inc. on the results of a Phase I study involvingin total over 120 adult healthy volunteers comparing safety andimmunogenicity of different doses of the Staphylococcus aureusvaccine. The Staphylococcus aureus vaccine is based on a conserved prote...

Inovio Biomedical's Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--May 17, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-basedvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat partners of the company will present new interim data from twophase I clinical trials of plasmid-based immunotherapies usingInovio's electropor...

GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Investigational vaccine could offer protectionfor infants against type b andmeningococcal disease — GlaxoSmithKline (GSK) announced results from aPhase II vaccine clinical study presented this week at thePediatri...

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants VersusCurrent Standard of Care and Shows Reduction of Medically AttendedOutpatient RSV- Related Lower Respiratory Infections - TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.today announced positive results from a large prospective trialconducted for prevention of respiratory syncytial virus (RSV). Thetrial compared...

Argos Therapeutics Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeuticstoday announced the presentation of data on the immunosuppressiveproperties of soluble CD83 at the 7th Joint American Transplantmeeting to be held in San Francisco, May 5-9. The presentationswill be made in collaboration with scientists at the University ofWestern Ontario. "These data suggest that soluble CD83 is able to exten...

Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine

Diamyd Medical AB (<a target="_blank" href="http://www.omxgroup.com/">www.omxgroup.com ticker: DIAM B; ticker DMYDY) STOCKHOLM, Sweden, May 3, 2007 – During a presentationmade in Linkoping, Sweden at the Sweden-Seattle Diabetes Conferencethis past week-end, Professor Johnny Ludvigsson, the Principal...

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2007 - XanthusPharmaceuticals, Inc today presented data demonstrating thatSymadex(TM) reversed the clinical and pathological signs of chronicdisease in an animal model for multiple sclerosis. The presentationwas made by Stephen J. Karlik, Ph.D., Professor of DiagnosticRadiology at the University of Western Ontario, London, Ontario,together with rese...

LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization

BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- LigoCytePharmaceuticals presented preclinical data today showing thatimmunization with their influenza virus-like particles (VLPs)induced heterosubtypic protection in a virus challenge study. Thecompany's data were presented by Dr. Joel Haynes, LigoCyte's seniordirector of vaccine development, at the Tenth Annual Conference onVaccine Research...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc.(Nasdaq: MEDI) today announced that seven abstracts will bepresented at the 2007 Pediatric Academic Societies' (PAS) AnnualMeeting demonstrating the company's commitment to advancing thescience of pediatric medicine. Data are from studies pertaining toMedImmune's approved and development-stage products, including bothmonoclon...